Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern

• DOI: 10.1016/j.isci.2022.103968
• Publication Date: 2022-02-23T00:03:22Z
• Authors: Anuradha Rao; Leda Bassit; Jessica Lin; Kiran Verma; Heather B. Bowers; Kimberly Pachura; Morgan Greenleaf; Julie Sullivan; Eric Lai; Richard S. Creager; Thomas Pribyl; John Blackwood; Anne L. Piantadosi; Raymond Schinazi; Greg S. Martin; Wilbur A. Lam
• Keywords: 2019-20 coronavirus outbreak

As the emergence of SARS-CoV-2 variants brings global pandemic to new levels, performance current rapid antigen tests against concern and interest (VOC/I) is significant public health concern. Here, we report assessment Abbot BinaxNOW COVID-19 Antigen Self-Test. Using genetically sequenced remnant clinical samples collected from individuals positive for SARS-CoV-2, assessed that currently pose threats. We measured limit detection various VOC/I in a blinded manner. successfully detected Omicron (B.1.1.529), Mu (B.1.621), Delta (B.1.617.2), Lambda (C.37), Gamma (P.1), Alpha (B.1.1.7), Beta (B.1.351), Eta (B.1.525), P.2 at low viral concentrations. also variant individual samples. Overall, these data indicate this inexpensive simple-to-use, FDA-authorized broadly distributed test can reliably detect Omicron, Delta, other VOC/I.